Prot #CMEK162X2109: A Phase IB Open-Label, Multi-Center, Dose Escalation and Expansion Study of Orally Administered MEK162 Plus BYL719 in Adult Patients with Selected Advanced Solid Tumors

Project: Research project

Project Details

StatusFinished
Effective start/end date12/1/13 → 7/31/15

Funding

  • Array BioPharma Incorporated (Prot #CMEK162X2109)